TICKERNOMICS Sign up
Last Update: 2023-10-04 11:36:15
Adamis Pharmaceuticals Corp ( ADMP ) https://www.adamispharmaceuticals.com
0.67USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
-93.88%
ADMP
SPY
36.71%
-98.69%
ADMP
SPY
70.96%
-99.69%
ADMP
SPY
262.36%
-99.82%
ADMP
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1.52
1.31
1.24
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.16
0.30
-0.13
-432.85
0.00
-0.04
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-162766.94
100.00
-846.42
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.4895
23.02
-303.20
1.45
Other Earnings and Cash Flow Stats:
Adamis Pharmaceuticals Corp ( ADMP ) Net Income TTM ($MM) is -17.77
Adamis Pharmaceuticals Corp ( ADMP ) Operating Income TTM ($MM) is -28.45
Adamis Pharmaceuticals Corp ( ADMP ) Owners' Earnings Annual ($MM) is -11.71
Adamis Pharmaceuticals Corp ( ADMP ) Current Price to Owners' Earnings ratio is -0.52
Adamis Pharmaceuticals Corp ( ADMP ) EBITDA TTM ($MM) is -27.54
Adamis Pharmaceuticals Corp ( ADMP ) EBITDA Margin is -846.42%
Capital Allocation:
Adamis Pharmaceuticals Corp ( ADMP ) has paid 0.00 dividends per share and bought back 147.413865 million shares in the past 12 months
Adamis Pharmaceuticals Corp ( ADMP ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Adamis Pharmaceuticals Corp ( ADMP ) Interest-bearing Debt ($MM) as of last quarter is 0
Adamis Pharmaceuticals Corp ( ADMP ) Annual Working Capital Investments ($MM) are -5
Adamis Pharmaceuticals Corp ( ADMP ) Book Value ($MM) as of last quarter is -12
Adamis Pharmaceuticals Corp ( ADMP ) Debt/Capital as of last quarter is 15%
Other Balance Sheet Stats:
Adamis Pharmaceuticals Corp ( ADMP ) has 0 million in cash on hand as of last quarter
Adamis Pharmaceuticals Corp ( ADMP ) has 15 million of liabilities due within 12 months, and long term debt 3 as of last quarter
Adamis Pharmaceuticals Corp ( ADMP ) has 2 common shares outstanding as of last quarter
Adamis Pharmaceuticals Corp ( ADMP ) has 0 million USD of preferred stock value
Academic Scores:
Adamis Pharmaceuticals Corp ( ADMP ) Altman Z-Score is -120.24 as of last quarter
Adamis Pharmaceuticals Corp ( ADMP ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
Adamis Pharmaceuticals Corp ( ADMP ) largest shareholder is UBS Group AG owning 286 shares at 0.00 ($MM) value
Marguglio David J.(SVP and Chief Business Officer) Sold -11859 shares of Adamis Pharmaceuticals Corp ( ADMP ) for the amount of $7116.59 on 2022-03-18
7.81% of Adamis Pharmaceuticals Corp ( ADMP ) is held by insiders, and 16.59% is held by institutions
Adamis Pharmaceuticals Corp ( ADMP ) went public on 1995-08-14
Other Adamis Pharmaceuticals Corp ( ADMP ) financial metrics:
FCF:-20.20
Unlevered Free Cash Flow:-20.62
EPS:-0.04
Operating Margin:-162766.94
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:53.13
Beta:1.45
Buffet's Owners Earnings:-11.71
Price to Owner's Earnings:-0.52
About Adamis Pharmaceuticals Corp ( ADMP ) :
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injectable pre-filled single dose syringe products for use in the emergency treatment of acute allergic reactions comprising anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was founded in 2006 and is headquartered in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.